RxDoctor Payments Data

Erika Connor, MD

Family Medicine · Randolph, NYNPI 1336136274

Payments from drug & device makers

$6,085in general payments, 2019–2025

Across 394 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$927
  • Lilly USA, LLC$565
  • GSK$393
  • Kowa Pharmaceuticals America, Inc.$301
  • Amgen$287
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,98598%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,085 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$90,811
Medicare patients
163
Services billed
2,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin143$124,690
Humira PenAdalimumab12$85,760
EliquisApixaban110$82,650
FarxigaDapagliflozin Propanediol92$78,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$74,752
TrulicityDulaglutide48$65,480
RybelsusSemaglutide44$62,863
XareltoRivaroxaban67$60,206
EntrestoSacubitril/Valsartan73$52,999
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$43,611
JanuviaSitagliptin Phosphate32$37,994
RexultiBrexpiprazole21$35,664
OzempicSemaglutide28$35,431
ProliaDenosumab20$34,859
MyrbetriqMirabegron35$28,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$224$159,941198 claims
Novo NordiskRybelsus, Ozempic$927$98,29472 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,033$94,513116 claims
PfizerEliquis, Paxlovid$235$88,021131 claims
GSKTrelegy Ellipta$393$74,75280 claims
Lilly USA, LLCTrulicity$565$65,48048 claims
NovartisEntresto$73$52,99973 claims
MerckJanuvia$143$37,99432 claims
Otsuka America Pharmaceutical, Inc.Rexulti$47$35,66421 claims
AmgenProlia$287$34,85920 claims
Astellas Pharma US IncMyrbetriq$98$28,09435 claims
AbbVieLinzess$282$13,29120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Randolph

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →